Чоловічий гіпогонадизм (Частина 1)

Ye.V. Luchytskyy; V.Yе. Luchytskyy; M.D. Tronko

doi:10.22141/2224-0721.13.4.2017.106658

PDF (Українська)

DOI: https://doi.org/10.22141/2224-0721.13.4.2017.106658

Keywords:

hypogonadism, testosterone

Ye.V. Luchytskyy

State Institution “V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine”, Kyiv, Ukraine, Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine

V.Yе. Luchytskyy

State Institution “V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine”, Kyiv, Ukraine

M.D. Tronko

State Institution “V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine”, Kyiv, Ukraine, Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine

Abstract

The first part of the review presents the current data on the prevalence of male hypogonadism, methods of diagnosing different forms of hypogonadism, describes the clinical manifestations of the most common forms of this disease.

How to Cite

Luchytskyy, Y., V. Luchytskyy, and M. Tronko. “Male Hypogonadism (Part 1)”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 13, no. 4, July 2017, pp. 281-9, doi:10.22141/2224-0721.13.4.2017.106658.

Issue

Vol. 13 No. 4 (2017)

Section

Lecture

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our edition uses the copyright terms of Creative Commons for open access journals.

Authors, who are published in this journal, agree with the following terms:

The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.

References

Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metabol. 2010;95:2536-9. doi: 10.1210/jc.2009-2354.

Nieschlag E, Behre HM, Nieschlag S, editors. Andrology: male reproductive health and dysfunction. 3rd ed. Springer-Verlag BBerlin Heidelberg; 2010. doi: 10.1007/978-3-540-78355-8_1.

Dohle GR, Arver S, Bettocchi C, et al. EAU Guidelines on Male Hypogonadism. EAU 2016. 26 p. Available from: http://uroweb.org/wp-content/uploads/18-Male-Hypogonadism_LR1.pdf

Brinkman AO. Molecular mechanisms of androgen action – a historical perspective. Methods Mol Biol. 2011;776:3. doi: 10.1007/978-1-61779-243-4_1.

de Ronde W, de Jong FH. Aromatase inhibitors in men: effects and therapeutic options. Reprod Biol Endocrinol. 2011;9:93. doi: 10.1186%2F1477-7827-9-93.

McLachlan RI, et al. Hormonal regulation of spermatogenesis in primates and man: insights for development of the male hormonal contraceptive. J Androl. 2002 Mar-Apr;23(2):149. PMID: 11868805.

Zitzmann M. Mechanisms of disease: pharmacogenetics of testosterone therapy in hypogonadal men. Nat Clin Pract Urol. 2007;4:161-6. doi: 10.1038/ncpuro0706.

Canale D, et al. Androgen receptor polymorphism (CAG repeats) and androgenicity. Clin Endocrinol. (Oxf). 2005;63:356-61. doi: 10.1111/j.1365-2265.2005.02354.x.

Nieschlag E, Behre HM, editors. Testosterone: action, deficiency, substitution. Cambridge. University Press; 2004.

Greenspan FS, Strewler GJ. Basic and Clinical Endocrinology. 5 ed. 1997. pp. 404-30.

Zitzmann M, Faber S, Nieschlag Е. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006 Nov;91(11):4335-43. doi: 10.1210/jc.2006-0401.

Dreval’ AV, Red’kin YuA. Age-related hypogonadism: basic principles of diagnostics and treatment. Rossijskij Medicinskij Zhurnal. 2016;1:29-31. (In Russian).

Luchytskyi EV, Luchytskyi VE, Pylypenko VM, authors. Tron’ko MD, Bol’shova OV, editors. Porushennja statevogo dozrіvannja. Klіnіchna endokrinologіja ditjachogo ta pіdlіtkovogo vіku [Violation of the sexual ripening. Clinical endocrinology of child's and juvenile age]. Кyiv: Zdorovya Ukrajiny; 2016. pp. 497-575. (In Ukrainian).

Tüttelmann F, Gromoll J. Novel genetic aspects of Klinefelter‘s syndrome. Mol Hum Reprod. 2010 Jul;16(6):386-95. doi: 10.1093/molehr/gaq019.

Pühse G, et al. Testosterone deficiency in testicular germ-cell cancer patients is not influenced by oncological treatment. Int JAndrol. 2011 Oct;34( P2t2):e351-7. doi: 10.1111/j.1365-2605.2010.01123.x.

Nord C, et al. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol. 2003 Sep;44(3):3228. PMID: 12932930.

Jaaskelainen J. Molecular biology of androgen insensitivity. Mol Cel Endocrinol. 2011 Apr;352(1-3):4-12. doi: 10.1016/j.mce.2011.08.006.

Tajar A, Huhtaniemi IT, O’Neill TW, et al. EMAS Group. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metabol. 2012 May;97(5):1508-16. doi: 10.1210/jc.2011-2513.

Lawrence KL, Stewart F, Larson BM. Approaches to male hypogonadism in primary care. The Nurse Pract. 2017;42:32-37. PMID: 28085783. PMCID: PMC5278890. doi: 10.1097/01.NPR.0000511774.51873.da.

Wu FC, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010 Jul;363:123-135. doi: 10.1056/NEJMoa0911101.

Morgentaler A, Zitzman M, Traish AM, et al. Fundamental Concepts Regarding Testosterone Deficiency and Treatment: International Expert Consensus Resolutions. Mayo Clin Proc. 2016;91(7):881-96. doi: 10.1016/j.mayocp.2016.04.007.